Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 10,755 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metastasis, Neoplasm Clear all
Completed Phase 2 Interventional

A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer

NCT01590719
View directory record Official record
Conditions
Gastric Cancer
Interventions
Placebo, Onartuzumab (MetMAb), Oxaliplatin, Folinic acid, Levofolinic acid, 5-Fluorouracil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
18
States / cities
Denver, Colorado • New Haven, Connecticut • Fort Myers, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 30, 2026, 3:18 PM EDT
Active, not recruiting Phase 2 Interventional

Olaparib In Metastatic Breast Cancer

NCT03344965
View directory record Official record
Conditions
Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation
Interventions
Olaparib
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
20
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 30, 2026, 3:18 PM EDT
Terminated Phase 2 Interventional Results available

Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer

NCT01937507
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
HAI with FOLFOX
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 30, 2026, 3:18 PM EDT
Completed No phase listed Observational

Pattern of Cell Death Following Neoadjuvant Therapy for Metastatic Colon Cancer

NCT00414492
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Oct 30, 2026, 3:18 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effect of Doxycycline in Patients With Amyloidosis

NCT01677286
View directory record Official record
Conditions
Amyloidosis
Interventions
Doxycycline 100 mg po bid x 12 months
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 30, 2026, 3:18 PM EDT
Terminated Phase 1 Interventional

Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia

NCT01491594
View directory record Official record
Conditions
Sarcoma, Soft Tissue, Osteosarcoma, Neoplasms, Connective and Soft Tissue
Interventions
Eltrombopag
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 82 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 30, 2026, 3:18 PM EDT
Recruiting Phase 1Phase 2 Interventional

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366
View directory record Official record
Conditions
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer, Cervical Cancer
Interventions
Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin, Itraconazole
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 3:18 PM EDT
Recruiting Phase 2 Interventional

Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.

NCT07594431
View directory record Official record
Conditions
Metastases, Metastatic Cancer
Interventions
LATTICE Radiotherapy, Standard radiotherapy
Radiation
Lead sponsor
Stanford University
Other
Eligibility
12 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 3:18 PM EDT
Completed Phase 1 Interventional

Study of Ixazomib and Erlotinib in Solid Tumors

NCT02942095
View directory record Official record
Conditions
Solid Tumors
Interventions
Ixazomib, Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 30, 2026, 3:18 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

NCT02575339
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer, HCC
Interventions
MLN0128, MLN0128 (RP2D), Sorafenib
Drug
Lead sponsor
Kathy Miller
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
Chicago, Illinois • Indianapolis, Indiana • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 30, 2026, 3:18 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma

NCT01350401
View directory record Official record
Conditions
Melanoma
Interventions
Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T
Genetic
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
New Haven, Connecticut • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 30, 2026, 3:18 PM EDT
Withdrawn Phase 2 Interventional

Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET

NCT03065712
View directory record Official record
Conditions
Breast Cancer
Interventions
F-18 Fluoroestradiol, Computed Tomography, Positron Emission Tomography, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 30, 2026, 3:18 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery

NCT02700230
View directory record Official record
Conditions
Metastatic Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1, Recurrent Malignant Peripheral Nerve Sheath Tumor
Interventions
Computed Tomography, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Quality-of-Life Assessment, Single Photon Emission Computed Tomography, Magnetic Resonance Imaging, Ultrasound Imaging, Biospecimen Collection, Biopsy, Questionnaire Administration
Procedure · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 30, 2026, 3:18 PM EDT
Not yet recruiting Phase 2 Interventional

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

NCT07612007
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Darizmetinib, Embolization Therapy, Hepatectomy, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 30, 2026, 3:18 PM EDT
Recruiting Phase 2 Interventional

Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

NCT06416007
View directory record Official record
Conditions
Cancer, Metastatic Cancer, Locally Advanced, Locally Advanced Solid Tumor, Locally Advanced Carcinoma
Interventions
Lattice therapy (LRT)
Radiation
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 30, 2026, 3:18 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

NCT03190967
View directory record Official record
Conditions
Breast Cancer, Brain Metastasis, Brain Cancer
Interventions
T-DM1, TMZ
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 30, 2026, 3:18 PM EDT
Completed Not applicable Interventional

Tka Assay for CDK4/6i

NCT06572800
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma
Interventions
DiviTum-TKa
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
18
States / cities
Derby, Connecticut • Fairfield, Connecticut • Glastonbury, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 30, 2026, 3:18 PM EDT
Completed Phase 1 Interventional

A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

NCT03215511
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
Selitrectinib (BAY2731954)
Drug
Lead sponsor
Bayer
Industry
Eligibility
1 Month and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 30, 2026, 3:18 PM EDT
Not yet recruiting Early Phase 1 Interventional

The Effects of Cannabis on Post Operative Recovery After Radical Cystectomy

NCT07577999
View directory record Official record
Conditions
Non-metastatic Bladder Cancer
Interventions
Cannabigerol
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 30, 2026, 3:18 PM EDT
Withdrawn Phase 2 Interventional

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

NCT02263898
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
Raf kinase inhibitor LGX818, binimetinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 30, 2026, 3:18 PM EDT
Completed Phase 1 Interventional

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

NCT02406521
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Pazopanib, Sorafenib, Radium-223
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 30, 2026, 3:18 PM EDT
Completed Phase 2 Interventional Results available

Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

NCT02601014
View directory record Official record
Conditions
Prostate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma
Interventions
Ipilimumab, Nivolumab, Enzalutamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 30, 2026, 3:18 PM EDT
Active, not recruiting Phase 2 Interventional

Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers

NCT03585114
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
[F-18] DCFPyL, PET/CT imaging
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 30, 2026, 3:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression

NCT00033514
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, erlotinib hydrochloride
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 30, 2026, 3:18 PM EDT